A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. - Wikidata - awgldk - TriplyDB

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33556988

about

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer Distinct genetic alterations in small cell carcinoma from different anatomic sites Emerging therapeutic agents for lung cancer Strategies for modern biomarker and drug development in oncology.Optofluidic device for the quantification of circulating tumor cells in breast cancer.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance Hypoxia/lncRNA-AK123072/EGFR pathway induced metastasis and invasion in gastric cancer.Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells.CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer.Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.MiR-31 Regulates Rho-Associated Kinase-Myosin Light Chain (ROCK-MLC) Pathway and Inhibits Gastric Cancer Invasion: Roles of RhoA Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2.AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors.Knockdown of EGFR inhibits growth and invasion of gastric cancer cells.EGFR-TKIs resistance via EGFR-independent signaling pathways.Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.

P2860

Q26801357-81F2171A-8CAD-4D5E-891B-C4A77D9132B3 Q27008242-420B5A6A-074B-4F50-9FBC-06CEFC9A5D8B Q28070165-0FAA2D25-1D36-4D4C-9131-ED9C960BCE7C Q30590270-C2C8D6FA-E3E0-4236-A7C3-2740239AB24D Q33808137-BDA34AAF-2C42-47BD-90C6-C552A7AB4E56 Q33873095-7E4DF971-10F5-4662-A755-1A9E1B286210 Q34712645-ED0EDB16-DA8F-40C8-81A7-BCAE2EAE281E Q34774854-5B4E48A4-A3B7-44B9-A0CF-576FD90002F8 Q36492594-7A8E24ED-38BD-4DF6-AA76-D4F09FAA058B Q36946655-469CCDAE-FC9A-4913-AAEC-D8D1BAE602E5 Q37252696-BA04794B-887A-4F7E-BB52-9E4BAE6889A4 Q38253835-9AF60F1B-2477-48DA-B710-308959933975 Q38728171-77C2A71F-40AE-4AC0-97C6-D1B62F20684F Q38825712-AE33533C-95FB-4038-AA95-CB2BD67C41AD Q41593135-1E011237-77F6-4523-A7FE-23472E9A38B3 Q42181490-4820288A-96A0-4B67-A85C-B7DBF8A965AC Q49887890-C674A318-AE8C-405A-96EC-938022043192 Q55028849-9D15B31E-C7F7-438C-948A-43E7C31BFC99

P2860

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33556988

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@ast

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@en

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@nl

type

label

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@ast

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@en

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@nl

prefLabel

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@ast

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@en

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@nl

P1433

Q33556988-12FDBB2A-4E3E-4F2B-AC4D-49360017DF71

P1476

Q33556988-F9624092-1745-4912-8051-CCFD1937EEAE

P2093

Q33556988-0F8B8623-14C3-4E3D-A8C8-21A367B71603

Q33556988-133E1A31-E02E-464B-B6E3-5FB28F2CC7F3

Q33556988-477B295C-6824-4D6D-A20F-CF9529F11E6B

Q33556988-5E9D8799-EBAC-4119-9AFA-467EDA6B1F4B

Q33556988-8F7A29C8-3F91-4DF5-B323-9C541F82C546

Q33556988-989BC282-C5E2-4DE0-8007-39B311866B14

Q33556988-BFF386F9-142E-43AA-9DCA-6EE4486EB363

Q33556988-CFADF577-5418-4254-9863-FDD4D554B745

Q33556988-D0EC87D9-46DC-4228-BD48-B16C56A75935

Q33556988-D13BB70F-32B3-45FE-8E5C-D5675826668E

P2860

Q33556988-082E0338-8E07-4B5B-A2F4-8C2C8236623B

Q33556988-2127A53E-F4BF-4BAD-B8C3-6F7D73A1F43E

Q33556988-24D7FF29-1246-44E2-82EC-93F95B842135

Q33556988-268B6E7F-B4AE-4793-AF4A-4E9EA319A11B

Q33556988-297B26F8-CD75-4620-B67F-2FE0A951DC46

Q33556988-2AEFF550-4226-4582-9C32-D7C37CC1C287

Q33556988-32F1E1B9-35F0-47F5-9F0C-138509C4313A

Q33556988-49B49C88-D68E-46CC-A4B7-E5CD30F76148

Q33556988-4AB5F233-CB43-4247-A81F-05E932C565EA

Q33556988-5993DE2C-5C46-4AB0-B983-BE2D4B8CB115

P2888

Q33556988-493C99A2-FDB3-4E27-9771-69E85C6E5AF3

P304

Q33556988-56496D6D-98F4-415C-81C3-AEBABF8C8F62

P31

Q33556988-C8913127-8715-491F-BB58-DA2A3C2ED02F

P356

Q33556988-90323783-7E41-408C-ABAC-A5654513BBCF

P478

Q33556988-682D8D99-29A1-4BF3-9555-29A6FEDEDCD2

P577

Q33556988-37890E82-64DB-4688-A253-C822C4568321

P5875

Q33556988-0B1DF63D-4583-46CB-AD98-1FCE09DDA7AF

P6179

Q33556988-A0E9E5CC-CAE8-455E-B3C1-393550814036

P698

Q33556988-6AC29E08-0581-4815-AFFD-60C16E65ED8C

P932

Q33556988-04C83AF1-71BA-4736-A7DB-6B4EFDAD9215

P356

P1433

Journal of Hematology & Oncology

P1476

A phase I study of AST1306, a ...... ts with advanced solid tumors.

@en

P2093

Dafang Zhong

http://www.w3.org/2001/XMLSchema#string

Jiachen Wang

http://www.w3.org/2001/XMLSchema#string

Jian Zhang

http://www.w3.org/2001/XMLSchema#string

Jin Li

http://www.w3.org/2001/XMLSchema#string

Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Junning Cao

http://www.w3.org/2001/XMLSchema#string

Naiqing Zhao

http://www.w3.org/2001/XMLSchema#string

Si Sun

http://www.w3.org/2001/XMLSchema#string

Wei Peng

http://www.w3.org/2001/XMLSchema#string

Xiaofang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Untangling the ErbB signalling network

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo

Detection of mutations in EGFR in circulating lung-cancer cells

P2888

P304

22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-8722-7-22

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260681727

http://www.w3.org/2001/XMLSchema#string

P6179

1031876263

http://www.w3.org/2001/XMLSchema#string

P698

24612546

http://www.w3.org/2001/XMLSchema#string

P932

4007625

http://www.w3.org/2001/XMLSchema#string